anti lamc2 antibody (Santa Cruz Biotechnology)
Structured Review

Anti Lamc2 Antibody, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 59 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+lamc2/Laminin+%CE%B3-2+Antibody/bio_rxiv__64898__2026__10__27__762113-92-15-19
Average 94 stars, based on 59 article reviews
Images
1) Product Images from "Keratin 17 Defines an Epithelial-Mesenchymal Transition-Associated Migratory Cell State in Pancreatic Ductal Adenocarcinoma"
Article Title: Keratin 17 Defines an Epithelial-Mesenchymal Transition-Associated Migratory Cell State in Pancreatic Ductal Adenocarcinoma
Journal: bioRxiv
doi: 10.64898/2026.10.27.762113
Figure Legend Snippet: (A) UMAP of all captured cells, colored by major cell type. (B) Re-clustering of the epithelial compartment resolves malignant and normal populations. (C) PCA projection of malignant cells colored by continuous KRT17 expression level, illustrating a gradient rather than a discrete bimodal distribution. (D) Hallmark pathway enrichment (normalized enrichment score, NES) in KRT17 -positive vs. KRT17 -negative malignant cells; EMT is the top-ranked pathway. Asterisks denote pathways with significant enrichment (adjusted p < 0.05). (E) GSEA enrichment plot for the Hallmark EMT gene set (NES = 3.06, FDR < 0.05). (F) Venn diagram of genes enriched in KRT17 -positive cells, KRT17 -negative cells, and the curated EMT/migration gene set, showing overlap between each group and the EMT/migration signature. (G) Volcano plot of differential EMT/migration gene expression in KRT17 -positive vs. KRT17 -negative malignant cells, with six selected EMT/migration markers (ANXA1, S100A4, GPC1, LAMC2, WWTR1, LAMA3) labeled. (H) Same comparison as (G) after filtering to genes with a minimum expression prevalence of 20% among malignant cells.
Techniques Used: Expressing, Migration, Gene Expression, Labeling, Comparison
Figure Legend Snippet: (A-C) Representative H&E images of intratumoral grade I, II, and III morphology. (D-F) Corresponding dual-plex IHC for K17 (green) and LAMC2 (brown) in an adjacent serial section. (G) Relative percentage of intratumoral grade (I/II/III) per case (n = 60), ordered by percent intratumoral grade III area. (H-J) Percentage of grade area occupied by each of four K17/LAMC2 categories within grade I (H), grade II (I), and grade III (J), showing progressive enrichment of the K17-positive/LAMC2-positive category and progressive loss of the K17-negative/LAMC2-negative category with worsening grade (Friedman test with Benjamini-Hochberg-corrected pairwise comparisons; all grade-to-grade comparisons significant, adjusted p < 0.05). Scale bars, 100 μm.
Techniques Used: Morphology
Figure Legend Snippet: (A) Leiden clustering of MACSima single-cell intensity data of all six EMT-associated markers and K17 (excluding PanCK), restricted to tumor cells, visualized by UMAP (N = 66 of 69 total cores with complete-panel staining; 410,605 tumor cells; 38 clusters). (B) K17 positivity overlaid on the same UMAP, with K17-positive cells concentrated within a discrete subset of clusters. (C) Marker enrichment across clusters ordered by K17 positivity (left) and cluster-level Spearman correlation of each marker with K17 (right): ANXA1 ρ = 0.68, LAMC2 ρ = 0.49, WWTR1 ρ = 0.24, S100A4 ρ = 0.15, LAMA3 ρ = 0.15, GPC1 ρ = −0.20. (D) Representative multiplex image showing K17 (red), LAMC2 (green), and PanCK (white) merge; arrows indicate co-expressing cells. (E) Representative multiplex image showing K17 (red), ANXA1 (green), and PanCK (white) merge; arrows indicate co-expressing cells. (F) Percentage of LAMC2-positive cells in K17-positive vs. K17-negative tumor cells (N = 67 cores, ****p < 0.0001). (G) Percentage of ANXA1-positive cells in K17-positive vs. K17-negative tumor cells (N = 69 cores, ****p < 0.0001). Boxes show the median and interquartile range, whiskers show the range, and “+” marks the mean. Wilcoxon matched-pairs signed-rank test. Scale bars, 50 μm.
Techniques Used: Single Cell, Staining, Marker, Multiplex Assay, Expressing
Figure Legend Snippet: CPTAC proteomic analyses identify LAMC2 as the strongest protein-level correlate of K17 among the six scRNA-seq-nominated markers and associate K17/LAMC2 co-expression with adverse survival. (A) Enrichment of 27 cancer-related hallmark pathways in K17-positive vs. K17-negative tumors (140 patients; FDR < 0.05); EMT ranks first. (B) GSEA enrichment plot for the Hallmark EMT gene set (NES = 3.041; FDR = 6.21 × 10⁻²⁸; n = 158 proteins). (C) Volcano plot of differential protein abundance, K17-positive vs. K17-negative tumors; LAMC2 (log2FC = 0.676; adjusted p = 0.0002) and additional keratins/basal/EMT-associated markers are labeled among the top differentially abundant proteins. (D) K17 protein abundance correlates with LAMC2 abundance (n = 140 patients; Spearman ρ = 0.46; p = 1.61 × 10⁻⁸). (E) Kaplan-Meier overall survival by four-group K17/LAMC2 co-expression status (n = 123 patients); the K17-positive/LAMC2-positive group (n = 44 patients) shows the worst survival. (F) Forest plot of a multivariable Cox proportional hazards model for overall survival, including K17/LAMC2 co-expression groups (reference: K17-negative/LAMC2-negative) adjusted for pathologic stage and age; K17-positive/LAMC2-positive remained the only significant independent predictor of worse survival (HR = 2.53; p = 0.0013).
Techniques Used: Expressing, Quantitative Proteomics, Labeling, Significance Assay
Figure Legend Snippet: (A-J) Representative multiplex images from ten regions of interest (ROIs), drawn from ten distinct tissue cores and ordered from lowest to highest proportion of poorly differentiated content, showing PanCK (white), K17 (red), and the six EMT/migration-associated markers: LAMC2 (green), ANXA1 (teal), S100A4 (purple), GPC1 (orange), WWTR1 (pink), LAMA3 (beige) with DAPI counterstain (blue). The progression spans predominantly glandular architecture (A) through ROIs with varying admixtures of morphology (B-I) to an ROI composed predominantly of poorly differentiated tumor cell clusters lacking glandular architecture (J). K17 is primarily observed within moderately to poorly differentiated tumor components across this progression, and along with its co-expression with LAMC2, it gives a yellow color. Scale bars, 50 μm.
Techniques Used: Multiplex Assay, Tissue, Migration, Morphology, Expressing
Related Articles
other:Article Title: Inhibition of AKT1 signaling promotes invasion and metastasis of non-small cell lung cancer cells with K-RAS or EGFR mutations Article Snippet: Other antibodies used include: anti-phospho-AKT3 (Ser472) (#AP3468a, Abgent), anti-integrin β1 (#610467, BD transduction Laboratories), anti-β-actin (#A5441, Sigma-Aldrich), and Immunohistochemistry:Article Title: Laminin γ2 accelerates non-alcoholic fatty liver disease progression by enhancing lipid accumulation and fibrogenesis in hepatocytes. Article Snippet: Non-alcoholic steatohepatitis (NASH) is characterized by hepatic lipid accumulation and fibrosis, yet the molecular mechanisms linking metabolic dysfunction to extracellular matrix (ECM) remodeling remain poorly defined.. This study investigated the role of laminin γ2 (LAMC2, encoded by Lamc2), a basement membrane component, in NASH pathogenesis.. Using a high-fat choline-deficient L-amino acid-defined (HF-CDAA) dietinduced murine NASH model and AML12 hepatocytes, we assessed LAMC2 expression via qPCR, immunohistochemistry, and lipidomics. Blocking Assay:Article Title: Laminin γ2 accelerates non-alcoholic fatty liver disease progression by enhancing lipid accumulation and fibrogenesis in hepatocytes. Article Snippet: Non-alcoholic steatohepatitis (NASH) is characterized by hepatic lipid accumulation and fibrosis, yet the molecular mechanisms linking metabolic dysfunction to extracellular matrix (ECM) remodeling remain poorly defined.. This study investigated the role of laminin γ2 (LAMC2, encoded by Lamc2), a basement membrane component, in NASH pathogenesis.. Using a high-fat choline-deficient L-amino acid-defined (HF-CDAA) dietinduced murine NASH model and AML12 hepatocytes, we assessed LAMC2 expression via qPCR, immunohistochemistry, and lipidomics. Incubation:Article Title: Laminin γ2 accelerates non-alcoholic fatty liver disease progression by enhancing lipid accumulation and fibrogenesis in hepatocytes. Article Snippet: Non-alcoholic steatohepatitis (NASH) is characterized by hepatic lipid accumulation and fibrosis, yet the molecular mechanisms linking metabolic dysfunction to extracellular matrix (ECM) remodeling remain poorly defined.. This study investigated the role of laminin γ2 (LAMC2, encoded by Lamc2), a basement membrane component, in NASH pathogenesis.. Using a high-fat choline-deficient L-amino acid-defined (HF-CDAA) dietinduced murine NASH model and AML12 hepatocytes, we assessed LAMC2 expression via qPCR, immunohistochemistry, and lipidomics. |


